13.31
前日終値:
$13.34
開ける:
$13.4
24時間の取引高:
353.02K
Relative Volume:
0.45
時価総額:
$867.48M
収益:
-
当期純損益:
$-119.67M
株価収益率:
-4.8755
EPS:
-2.73
ネットキャッシュフロー:
$-97.30M
1週間 パフォーマンス:
-7.05%
1か月 パフォーマンス:
-3.34%
6か月 パフォーマンス:
+29.73%
1年 パフォーマンス:
-0.82%
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
名前
Mineralys Therapeutics Inc
セクター
電話
(888) 378-6240
住所
150 N. RADNOR CHESTER ROAD, RADNOR
MLYS を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
MLYS
Mineralys Therapeutics Inc
|
13.31 | 869.44M | 0 | -119.67M | -97.30M | -2.73 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-06-11 | 開始されました | Jefferies | Hold |
2024-07-10 | 開始されました | H.C. Wainwright | Buy |
2024-04-02 | 開始されました | Goldman | Buy |
2023-03-07 | 開始されました | BofA Securities | Buy |
2023-03-07 | 開始されました | Credit Suisse | Outperform |
2023-03-07 | 開始されました | Evercore ISI | Outperform |
2023-03-07 | 開始されました | Guggenheim | Buy |
2023-03-07 | 開始されました | Stifel | Buy |
2023-03-07 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Mineralys Therapeutics Inc (MLYS) 最新ニュース
What drives Mineralys Therapeutics Inc. stock priceTriple-digit return opportunities - Autocar Professional
What analysts say about Mineralys Therapeutics Inc. stockRecord-breaking gains - Autocar Professional
Mineralys Therapeutics Inc. Stock Analysis and ForecastMarket-crushing profits - jammulinksnews.com
Is Mineralys Therapeutics Inc. a good long term investmentFree Stock Selection - jammulinksnews.com
Mineralys Therapeutics Reports Positive Phase 2 Trial Results for Lorundrostat in Hypertension and CKD - MSN
(MLYS) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Mineralys Therapeutics CFO Adam Levy sells $155k in stock By Investing.com - Investing.com South Africa
Mineralys Therapeutics CEO Congleton sells $230k in shares By Investing.com - Investing.com South Africa
MLYS SEC FilingsMineralys Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Mineralys Therapeutics, Inc. (MLYS) Receives a Hold from Jefferies - The Globe and Mail
Jefferies Initiates Mineralys Therapeutics(MLYS.US) With Hold Rating, Announces Target Price $15 - 富途牛牛
Promising Investment Opportunity in Mineralys Therapeutics Driven by Lorundrostat’s Clinical Success - TipRanks
Jefferies maintains Hold rating on Mineralys stock amid AstraZeneca data By Investing.com - Investing.com South Africa
Jefferies maintains Hold rating on Mineralys stock amid AstraZeneca data - Investing.com Australia
Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat - insights.citeline.com
Mineralys Therapeutics: Navigating Cash Burn and Clinical Triumphs in a $200B Market - AInvest
Mineralys Therapeutics Publishes Phase 3 Trial Results in JAMA for Hypertension Treatment - MSN
Mineralys Therapeutics Reports Positive Topline Data from Phase 2 Explore-CKD Trial of Lorundrostat - MSN
Here's Why We're Watching Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation - Yahoo.co
Verrica Pharmaceuticals Advances Global Phase 3 Trial for YCANTH with Amended Torii Agreement - MyChesCo
Mineralys reports positive phase 3 results for hypertension drug By Investing.com - Investing.com Canada
Mineralys Therapeutics, Inc.(NasdaqGS: MLYS) dropped from Russell 2000 Value Index - MarketScreener
Mineralys reports positive phase 3 results for hypertension drug - Investing.com
(MLYS) Long Term Investment Analysis - news.stocktradersdaily.com
Is Mineralys Therapeutics, Inc. technically bullish or bearish? - MarketsMojo
Mineralys Eyes NDA As Lorundrostat Scores CKD Win In Race With AstraZeneca - insights.citeline.com
Lorundrostat Shows Clinically Meaningful Outcomes in Patients With CKD and Hypertension - Pharmacy Times
Mineralys stock holds Buy rating at H.C. Wainwright after CKD trial - Investing.com Canada
Mineralys enhances lorundrostat data package ahead of planned NDA - The Pharma Letter
Mineralys Therapeutics Inc (MLYS) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):